Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer

Dobilas, Arturas LU ; Chen, Yilun LU ; Brueffer, Christian LU orcid ; Leandersson, Pia LU orcid ; Saal, Lao H LU orcid and Borgfeldt, Christer LU (2023) In Cancer Genomics & Proteomics 20(6 suppl). p.763-770
Abstract

BACKGROUND/AIM: Circulating tumor DNA (ctDNA), which is shed from cancer cells into the bloodstream, offers a potential minimally invasive approach for cancer diagnosis and monitoring. This research aimed to assess the preoperative ctDNA levels in ovarian tumors patients' plasma and establish correlations with clinicopathological parameters and patient prognosis.

PATIENTS AND METHODS: Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples,... (More)

BACKGROUND/AIM: Circulating tumor DNA (ctDNA), which is shed from cancer cells into the bloodstream, offers a potential minimally invasive approach for cancer diagnosis and monitoring. This research aimed to assess the preoperative ctDNA levels in ovarian tumors patients' plasma and establish correlations with clinicopathological parameters and patient prognosis.

PATIENTS AND METHODS: Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples, obtained prior to surgery, to evaluate ctDNA levels in terms of mutant copy number/ml and variant allele frequency.

RESULTS: Somatic mutations were found in 24 tumor samples, 17 of which were from ovarian cancer patients. The most frequently mutated gene was TP53. Preoperative plasma ctDNA levels were detected in 14 of the 24 patients. With higher stage, plasma ctDNA mutant concentration increased (p for trend <0.001). The overall survival of cancer patients with more than 10 ctDNA mutant copies/ml in plasma was significantly worse (p=0.008).

CONCLUSION: Pre-operative ctDNA measurement in ovarian cancer patients' plasma holds promise as a predictive biomarker for tumor staging and prognosis.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Ovarian cancer, Gynecological cancer disease, ctDNA, Liquid biopsy, Somatic mutation
in
Cancer Genomics & Proteomics
volume
20
issue
6 suppl
pages
8 pages
publisher
International Institute of Anticancer Research
external identifiers
  • scopus:85178515512
  • pmid:38035709
ISSN
1790-6245
DOI
10.21873/cgp.20423
language
English
LU publication?
yes
additional info
Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
id
f2834e96-72ae-40a5-a953-2c83789cb5e0
date added to LUP
2023-12-13 11:30:47
date last changed
2024-04-12 20:00:09
@article{f2834e96-72ae-40a5-a953-2c83789cb5e0,
  abstract     = {{<p>BACKGROUND/AIM: Circulating tumor DNA (ctDNA), which is shed from cancer cells into the bloodstream, offers a potential minimally invasive approach for cancer diagnosis and monitoring. This research aimed to assess the preoperative ctDNA levels in ovarian tumors patients' plasma and establish correlations with clinicopathological parameters and patient prognosis.</p><p>PATIENTS AND METHODS: Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples, obtained prior to surgery, to evaluate ctDNA levels in terms of mutant copy number/ml and variant allele frequency.</p><p>RESULTS: Somatic mutations were found in 24 tumor samples, 17 of which were from ovarian cancer patients. The most frequently mutated gene was TP53. Preoperative plasma ctDNA levels were detected in 14 of the 24 patients. With higher stage, plasma ctDNA mutant concentration increased (p for trend &lt;0.001). The overall survival of cancer patients with more than 10 ctDNA mutant copies/ml in plasma was significantly worse (p=0.008).</p><p>CONCLUSION: Pre-operative ctDNA measurement in ovarian cancer patients' plasma holds promise as a predictive biomarker for tumor staging and prognosis.</p>}},
  author       = {{Dobilas, Arturas and Chen, Yilun and Brueffer, Christian and Leandersson, Pia and Saal, Lao H and Borgfeldt, Christer}},
  issn         = {{1790-6245}},
  keywords     = {{Ovarian cancer; Gynecological cancer disease; ctDNA; Liquid biopsy; Somatic mutation}},
  language     = {{eng}},
  month        = {{11}},
  number       = {{6 suppl}},
  pages        = {{763--770}},
  publisher    = {{International Institute of Anticancer Research}},
  series       = {{Cancer Genomics & Proteomics}},
  title        = {{Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer}},
  url          = {{http://dx.doi.org/10.21873/cgp.20423}},
  doi          = {{10.21873/cgp.20423}},
  volume       = {{20}},
  year         = {{2023}},
}